Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer by Govindan, Ramaswamy & et al,




Pooled systemic efficacy and safety data from the
pivotal phase II studies (NP28673 and NP28761)
of alectinib in ALK-positive non-small cell lung
cancer
Ramaswamy Govindan
Washington University School of Medicine in St. Louis
et al
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Govindan, Ramaswamy and et al, ,"Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and
NP28761) of alectinib in ALK-positive non-small cell lung cancer." Journal of Thoracic Oncology.12,10. 1552-1560. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/6923
ORIGINAL ARTICLE
Pooled Systemic Efﬁcacy and Safety Data from the
Pivotal Phase II Studies (NP28673 and NP28761) of
Alectinib in ALK-positive Non-Small Cell Lung Cancer
James Chih-Hsin Yang, MD, PhD,a,* Sai-Hong Ignatius Ou, MD, PhD,b
Luigi De Petris, MD,c Shirish Gadgeel, MD,d Leena Gandhi, MD, PhD,e
Dong-Wan Kim, MD, PhD,f Fabrice Barlesi, MD, PhD,g Ramaswamy Govindan, MD,h
Anne-Marie C. Dingemans, MD, PhD,i Lucio Crino, MD,j Herve Lena, MD,k
Sanjay Popat, PhD,l Jin Seok Ahn, MD,m Eric Dansin, MD,n Sophie Golding, MSc,o
Walter Bordogna, PhD,o Bogdana Balas, MD,o Peter N. Morcos, PharmD,p
Ali Zeaiter, MD,o Alice T. Shaw, PhDq
aDepartment of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Centre,
Taipei, Taiwan
bChao Family Comprehensive Cancer Centre, University of California Irvine School of Medicine, Orange, California
cOncology, Karolinska University Hospital, Stockholm, Sweden
dKarmanos Cancer Institute, Wayne State University, Detroit, Michigan
eNew York University, Perlmutter Cancer Center, New York University School of Medicine, New York, New York
fSeoul National University Hospital, Seoul, Republic of Korea
gAix Marseille University; Assistance Publique Hôpitaux de Marseille, Marseille, France
hDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
iMaastricht University Medical Centre, Maastricht, The Netherlands
jIstituto Scientiﬁco Romagnolo per lo Studio e la cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientiﬁco,
Meloda, Italy
kCentre Hospitalier Universitaire, Rennes University, Rennes, France
lRoyal Marsden Hospital, London, United Kingdom
mSamsung Medical Centre, Seoul, Republic of Korea
nCentre Régional de Lutte Contre le Cancer Oscar-Lambret, Lille, France
oF. Hoffmann-La Roche Ltd., Basel, Switzerland
pF. Hoffmann-La Roche, Innovation Center, New York, New York
qMassachusetts General Hospital Cancer Centre, Harvard Medical School, Boston, Massachusetts
Received 22 May 2017; revised 27 June 2017; accepted 29 June 2017
Available online - 5 July 2017
*Corresponding author.
Disclosure: Dr. Yang has received advisory board fees from Boehringer
Ingelheim, Bayer, AstraZeneca, Roche/Genentech, Chugai, Clovis
Oncology, Eli Lilly, Merck Sharp and Dohme, Merck Serono, Pﬁzer,
Novartis, Celgene, Merrimack, Yuhan Pharmaceuticals, and Daiichi
Sankyo. Dr. Ou has received personal fees for Pﬁzer, AstraZeneca,
ARIAD, and Roche outside the submitted work. Dr. De Petris has
received personal fees from Roche, AstraZeneca, and Bristol-Myers
Squibb. Dr. Gadgeel has received consultancy fees from Boehringer
Ingelheim, ARIAD, Novartis, and Genentech. Dr. Gandhi has received
consultancy fees from Genentech/Roche, Pﬁzer, Merck, Abbvie, and
AstraZeneca and personal fees from Merck and Bristol-Myers Squibb
IION Foundation. Dr. Kim has received personal fees from Roche. Dr.
Barlesi has received consulting fees from Roche. Dr. Govindan has
received travel accommodation fees and consulting fees from Merck,
Boehringer Ingelheim, Celgene, Roche, Stemcentrix, and Abbe Vie
and consultancy fees from GlaxoSmithKline, Clovis, and Helsinn
Healthcare. Dr. Dingemans has received consultancy fees from Eli
Lilly, AstraZeneca, Clovis, Boehringer Ingelheim, and Merck Sharp
and Dohme. Dr. Lena reports advisory board membership for Roche,
Merck Sharp and Dohme, Bristol-Myers Squibb, Novartis, Pﬁzer, and
AstraZeneca and has been reimbursed for meeting expenses from
Roche, Merck Sharp and Dohme, Bristol-Myers Squibb, Lilly, and
Amgen. Dr. Popat has received personal fees from Roche, Pﬁzer, and
Novartis outside the submitted work. Dr. Dansin has received
personal fees from Bristol-Myers Squibb, AstraZeneca, and Roche.
Ms. Golding, Dr. Bordogna, Dr. Balas, Mr. Morcos, and Dr. Zeaiter
are employees of and have stock ownership in Roche. Dr. Shaw has
received consulting fees from Ignyta and Taiho and advisory board
fees from Pﬁzer, Novartis, Genentech/Roche, Ariad, Daiichi-Sankyo,
Blueprint Medicines, Loxo, EMD Serono, and Foundation Medicine.
The remaining authors declare no conﬂict of interest.
Previously published in abstract form as Yang et al. Pooled efﬁcacy and
safety data from two phase II studies (NP28673 and NP28761) of
alectinib in ALK-positive non-small-cell lung cancer (NSCLC) [abstract].
J Thorac Oncol. 2017;12:S1170–S1171.
Address for correspondence: James Chih-Hsin Yang, MD, PhD, Depart-
ment of Oncology, National Taiwan University Hospital, 7, Chung-Shan
South Road, Taipei, Taiwan 100. E-mail: chihyang@ntu.edu.tw
ª 2017 International Association for the Study of Lung Cancer.
Published by Elsevier Inc. This is an open access article under the




Journal of Thoracic Oncology Vol. 12 No. 10: 1552-1560
ABSTRACT
Introduction: Alectinib demonstrated clinical efﬁcacy
and an acceptable safety proﬁle in two phase II studies
(NP28761 and NP28673). Here we report the pooled efﬁ-
cacy and safety data after 15 and 18 months more follow-up
than in the respective primary analyses.
Methods: Enrolled patients had ALK receptor tyrosine ki-
nase gene (ALK)-positive NSCLC and had progressed while
taking, or could not tolerate, crizotinib. Patients received oral
alectinib, 600 mg twice daily. The primary end point in both
studies was objective response rate assessed by an inde-
pendent review committee (IRC) using the Response Eval-
uation Criteria in Solid Tumors, version 1.1. Secondary end
points included disease control rate, duration of response,
progression-free survival, overall survival, and safety.
Results: The pooled data set included 225 patients (n¼ 138
in NP28673 and n ¼ 87 in NP28761). The response-
evaluable population included 189 patients (84% [n ¼ 122
in NP28673 and n ¼ 67 in NP28761]). In the response-
evaluable population, objective response rate as assessed
by the IRC was 51.3% (95% conﬁdence interval [CI]: 44.0–
58.6 [all PRs]), the disease control rate was 78.8% (95% CI:
72.3–84.4), and the median duration of response was 14.9
months (95% CI: 11.1–20.4) after 58% of events. Median
progression-free survival as assessed by the IRC was 8.3
months (95% CI: 7.0–11.3) and median overall survival was
26.0 months (95% CI: 21.4–not estimable). Grade 3 or higher
adverse events (AEs) occurred in 40% of patients, 6% of
patients had treatment withdrawn on account of AEs, and
33% had AEs leading to dose interruptions/modiﬁcation.
Conclusions: This pooled data analysis conﬁrmed the
robust systemic efﬁcacy of alectinib in ALK-positive NSCLC
with a durable response rate. Alectinib also had an accept-
able safety proﬁle with a longer duration of follow-up.
 2017 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Alectinib; Non–small cell lung cancer; NP28673;
NP28761; Pooled analysis
Introduction
NSCLC harboring a chromosomal rearrangement of
the anaplastic lymphoma kinase (ALK) gene (ALK-
positive NSCLC), represents a distinct molecular subset
of the disease, which affects approximately 5% of
patients.1 Crizotinib is the current standard of care for
ALK-positive NSCLC and has extended progression-free
survival (PFS) compared with cytotoxic chemotherapy
(10.9 months versus 7.7 months, respectively) in the
ﬁrst- and second-line treatment setting.2,3 Unfortunately,
almost half of crizotinib-treated patients relapse within
the ﬁrst year. This is usually a result of poor control of
disease within the central nervous system (CNS), which
is the most common site of disease progression,4,5 or
secondary ALK resistance mutations.6–8
Second-generation anaplastic lymphoma kinase (ALK)
inhibitors have been developedwith the aim of improving
efﬁcacy in patients with ALK-positive NSCLC, including
those with CNS metastases. The ALK inhibitor ceritinib
was granted accelerated approval by the U.S. Food and
Drug Administration (FDA) in 2014 for use in patients
with ALK-positive, metastatic NSCLC who had progressed
while taking, or were intolerant of, crizotinib.9 The
European Medicines Agency subsequently approved
ceritinib in 2015 for use with the same indication.10 The
approvals were based on a phase I and phase II study of
ceritinib in patients with ALK-positive NSCLC, which
demonstrated median PFS times of 5.7 to 6.9 months and
objective response rates (ORRs) of 39% to 56%.11,12
Recently, the FDA approval was extended to treatment-
naive patients with metastatic ALK-positive NSCLC.13
The extended approval was based on results from the
ASCEND-4 trial, which demonstrated superior PFS with
ceritinib versus with platinum-pemetrexed doublet
chemotherapy in patients with treatment-naive, ALK-
positive NSCLC (median PFS of 16.6 versus 8.1 months)
(hazard ratio [HR] ¼ 0.55, 95% conﬁdence interval [CI]:
0.42–0.73, p< 0.0001)14; a similar trend was observed in
patients with CNS metastases at baseline, but it was not
signiﬁcant. ORRs were improved with ceritinib versus
with chemotherapy in the overall study population (73%
versus 27%) and in those with measurable CNS disease at
baseline (46% versus 21%).14
Alectinib is a potent and highly selective ALK inhib-
itor that has demonstrated both systemic and CNS efﬁ-
cacy in ALK-positive NSCLC in a number of studies.15–18
Alectinib was approved in Japan in 2014 for the treat-
ment of ALK inhibitor–naive patients with ALK-positive
NSCLC after the results of a phase I/II study (AF001-JP).
This study reported a high ORR of 93.5% (95% CI:
82–99); follow-up for this study is still ongoing, with a
3-year PFS rate of 62% (95% CI: 45–75).19 Similarly,
signiﬁcant clinical activity was reported with alectinib in
two pivotal phase II studies, one global (NP28673
[NCT01801111]) and one North American (NP28761
[NCT01871805]), in patients with ALK-positive NSCLC
who had previously received crizotinib. ORRs of 50.8%
(95% CI: 41.6–60.0) and 52.2% (95% CI: 39.7–64.6)
were observed in NP28673 and NP28761, respectively
(data cutoff April 27, 2015), with a median duration of
response (DOR) of 14.1 months (95% CI: 10.9–not esti-
mable [NE] [44% of events] versus 13.5 months (95%
CI: 6.7–NE [40% of events]), respectively. Alectinib was
well tolerated in the global and North American studies,
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as reﬂected by the rates of dose interruptions (23% and
36%, respectively), dose reductions (10% and 16%,
respectively), and withdrawals due to adverse events
(AEs) (9% and 2%, respectively) reported (data cutoff
date April 27, 2015).17,18 Data from these two phase II
studies led to the accelerated approval of alectinib in
2015 by the FDA for treatment of patients with ALK-
positive NSCLC who progressed while taking, or were
intolerant of, crizotinib.20 Alectinib has also received
conditional approval for the same patient population
from the European Medicines Agency. Data from the
ﬁrst-line, phase III, global ALEX study demonstrated that
patients treated with alectinib had a longer PFS than
patients treated with crizotinib.21
Here, we present pooled efﬁcacy and safety analyses
from these phase II studies with 15 and 18 months more
follow-up than in the respective primary analyses for
NP28761 (data cutoff of January 22, 2016 versus
October 24, 2014) and NP28673 (data cutoff of February
1, 2016 versus August 18, 2014).
Methods
Study Design
NP28673 and NP28761 were phase II, single-arm,
open-label, multicenter studies. NP28673 was conduct-
ed across 16 countries at 56 sites and patients were
enrolled between June 20, 2013, and April 23, 2014.
NP28761 was undertaken in 27 centers across the United
States and Canada, with patients enrolled between May 3,
2012, and August 4, 2014. This time frame also included a
phase I dose-ﬁnding step; hence, the phase II portion of
the study commenced on September 4, 2013. Both studies
were undertaken in accordance with the principles of the
Declaration of Helsinki and Good Clinical Practice
Guidelines, and written informed consent was obtained
from all patients. The full methodology for each study has
been published previously.17,18
Eligibility Criteria
Both studies enrolled patients who were 18 years or
older with locally advanced or metastatic ALK-positive
NSCLC, as assessed by an FDA-approved ﬂuorescence in
situ hybridization test. Eligible patients had an Eastern
Cooperative Oncology Group (ECOG) performance status
(PS) of 2 or lower and had progressed while taking crizo-
tinib. Patientswith asymptomatic baseline CNSmetastases
(treated or untreated with radiation) and those who had
received prior chemotherapy were permitted to enroll in
both studies. Patients were excluded if they had received
prior ALK inhibitor treatment other than crizotinib.
Study Treatment
All patients received 600 mg of alectinib orally twice
daily with a meal, until disease progression, unacceptable
toxicity, withdrawal, or death. In both studies there was a
minimumwashout period of 7 days between the last dose
of crizotinib and the ﬁrst dose of alectinib.
Study End Points
The primary end point of the pooled analysis was
ORR assessed by an independent review committee
(IRC) using the Response Evaluation Criteria in Solid
Tumors, version 1.1. The secondary end points for both
studies included disease control rate (DCR), DOR, PFS,
overall survival (OS), and safety. CNS secondary end
points were also evaluated, including CNS ORR and CNS
DOR, and will be reported in a separate analysis.
Statistical Analysis
Response end points were assessed in the response-
evaluable (RE) population, which comprised patients
with measurable disease at baseline who received at
least one dose of alectinib. The safety population
comprised all patients who received at least one dose of
alectinib. ORR was deﬁned as the proportion of patients
in the RE population who achieved a best overall
response of conﬁrmed complete response (CR) or partial
response (PR). PFS and OS were assessed in the safety
population. PFS was calculated from the date of ﬁrst
dose of alectinib until disease progression or death. OS
was calculated from the date of ﬁrst dose of alectinib
until death. Time-to-event data (PFS, OS, and DOR) were
estimated by Kaplan-Meier analyses.
Results
Patients
The pooled data set comprised 225 patients (138
patients from the study NP28673 and 87 patients from
the study NP28761) (Supplementary Fig. 1). The RE
population according to the IRC included 189 patients
(84%), comprising 122 patients from NP28673 and 67
patients from NP28761. Baseline characteristics were
similar across both studies (Table 1). Brieﬂy, the median
patient age was 53 years (range 22–79), 67% of patients
had an ECOG PS of 1 or 2, and most patients (74%) were
white. Overall, 136 patients (60%) had baseline CNS
metastases and 174 (77%) had received prior chemo-
therapy (Table 1).
Efﬁcacy
At the data cutoff (February 1, 2016, for NP28673
and January 22, 2016, for NP28761), the median follow-
up for the pooled data set was 18.8 months (range 0.6–
29.7). In the RE population, the ORR assessed by the IRC
was 51.3% (95% CI: 44.0–58.6), with 97 of 189 patients
achieving a PR; there were no CRs. Stable disease was
reported in 52 of 189 patients (28%), giving a DCR of
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78.8% (95% CI: 72.3–84.4). The median DOR was 14.9
months (95% CI: 11.1–20.4) after 58% of events.
Of the patients who had received prior chemotherapy
in the RE population (n ¼ 148), 73 (49%) achieved a PR;
there were no CRs, giving an IRC-assessed ORR of 49.3%
(95% CI: 41.0–57.7). In total, 44 of 148 patients (30%)
had stable disease, resulting in a DCR of 79.1% (95% CI:
71.6–85.3). The median DOR (based on 59% of events)
in this subgroup was also 14.9 months (95% CI: 11.0–
21.9).
Overall, 24 of 41 chemotherapy-naive patients in
the RE population (59%) achieved a PR; there were no
CRs, giving an IRC-assessed ORR of 58.5% (95% CI:
42.1–73.7). Stable disease was reported in eight of 41
patients (20%) giving a DCR in this population of 78.0%
(95% CI: 62.4–89.4). The median DOR was 11.2 months
(95% CI: 8.0–NE) after 54% of events.
A subgroup analysis of IRC-assessed ORR was per-
formed to evaluate different prognostic factors, including
sex, race, ECOG PS, CNS metastases at baseline, smoking
status, and prior chemotherapy. ORR rates were gener-
ally consistent across most subgroups. Patients with an
ECOG PS of 0 had a numerically higher response rate
compared with patients with an ECOG PS of 1 or 2
(65.6% [95% CI: 52.3–77.3] versus 45.0% [95% CI:
35.6–54.8] or 41.2% [95% CI: 18.4–67.1], respectively).
The analysis also showed a higher response rate in pa-
tients who were never-smokers at baseline than in those
who were past smokers (55.9% [95% CI: 46.8–64.7]
versus 39.0% [95% CI: 26.5–52.6], respectively)










Median age (range), y 54 (29–79) 52 (22–79) 2 y 53 (22–79)
Sex, n (%)
Male 39 (45) 61 (44) 1 100 (44)
Female 48 (55) 77 (56) 1 125 (56)
ECOG PS, n (%)
0 30 (34) 44 (32) 2 74 (33)
1 48 (55) 81 (59) 4 129 (57)
2 9 (10) 13 (9) 1 22 (10)
Race, n (%)
White 73 (84) 93 (67) 17 166 (74)
Asian 7 (8) 36 (26) 18 43 (19)
Other 3 (3) 4 (3) 0 7 (3)
Black/African American 3 (3) 1 (0.7) 2.3 4 (2)
Multiple 1 (1) 0 (0) 1 7 (3)
Unknown 0 3 (2) 2 1 (0.4)
American Indian/Alaska native 0 1 (0.7) 0.7 1 (0.4)
CNS metastases, n (%)
Yes 52 (60) 84 (61) 1 136 (60)
No 35 (40) 54 (39) 1 89 (40)
Histologic subtype, n (%)
Adenocarcinoma 82 (94) 133 (96) 2 215 (96)
Other 5 (6) 5 (4) 2 10 (4)
Prior chemotherapy, n (%)
Yes 64 (74) 110 (80) 6 174 (77)
No 23 (26) 28 (20) 6 51 (23)
Crizotinib þ prior therapies
Crizotinib only 23 (26) 28 (20) 6 51 (23)
þ1 therapy 0 52 (38) 38 52 (23)
þ2 therapies 19 (22) 16 (12) 10 35 (16)
þ3 therapies 18 (21) 17 (12) 9 35 (16)
þ4 therapies 14 (16) 16 (12) 4 30 (13)
þ5 therapies 8 (9) 4 (3) 6 12 (5)
6 therapies 5 (6) 5 (4) 2 10 (4)
Smoking status
Active smoker 0 3 (2) 2 3 (1)
Past smoker 33 (38) 39 (28) 10 72 (32)
Never-smoker 54 (62) 96 (70) 8 150 (67)
ITT, intent-to-treat; ECOG, Eastern Cooperative Oncology Group; PS, performance status; CNS, central nervous system.
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(Table 2). However, it should be noted that the sub-
groups were relatively small and conﬁdence intervals
were overlapping.
In the pooled population, 156 of 225 patients (69%)
had a PFS event according to the IRC at the data cutoff.
The median PFS was 8.3 months (95% CI: 7.0–11.3)
(Fig. 1) and the 6-month event-free rate was 59.9%
(95% CI: 53.5–66.4). For patients who had received only
crizotinib treatment before receiving alectinib (51 of 225
[23%]), the median PFS was 8.4 months (95% CI: 5.6–
16.6). With regard to OS, 96 of 225 patients (43%) had
an OS event at the data cutoff. The median OS was 26.0
months (95% CI: 21.4–NE) and the 6-month event-free
rate was 85.3% (95% CI: 80.6–89.9) (Fig. 2).
Safety
Safety was evaluated in the pooled safety population
of 225 patients (138 patients from the study NP28673
and 87 patients from the study NP28761). The mean
dose intensity of alectinib was 94.1%.
AEs occurring at a frequency of more than 20%
(any grade) were constipation (38%), fatigue (34%),
peripheral edema (28%), myalgia (25%), nausea
(23%), cough (21%), and headache (21%). A summary
of AEs occurring at a frequency of more than 10% are
shown in Table 3. Grade 3 to 5 AEs occurred in 40% of
patients; the most common were dyspnea (4%),
elevated levels of blood creatine phosphokinase (4%),
alanine transaminase (3%), and aspartate trans-
aminase (3%). Seven patients (3%) died during the
study, including two of hemorrhage and one each of
dyspnea, endocarditis, intestinal perforation, pulmo-
nary embolism, and an unspeciﬁed cause. Only
two deaths (1%) were considered by the investigator
to be treatment related (hemorrhage and intestinal
perforation).
Table 2. Subgroup Analyses of IRC Objective Response Rate in the Pooled Population (IRC RE Population)
Characteristic Patients per Subgroup (n ¼ 189)
Responders per Subgroup
n (%) 95% CI
Sex
Male 88 46 (52.3) 41.4–63.0
Female 101 51 (50.5) 40.4–60.6
Race
White 137 70 (51.1) 42.4–59.7
Asian 38 23 (60.5) 43.4–76.0
Other 14 4 (28.6) 8.4–58.1
ECOG PS at baseline
0 61 40 (65.6) 52.3–77.3
1 111 50 (45.0) 35.6–54.8
2 17 7 (41.2) 18.4–67.1
CNS metastases at baseline
Yes 113 55 (48.7) 39.2–58.3
No 76 42 (55.3) 43.4–66.7
Prior chemotherapy
Yes 148 73 (49.3) 41.0–57.7
No 41 24 (58.5) 42.1–73.7
No. of prior regimens
1 or 2 89 48 (53.9) 43.0–64.6
3–9 100 49 (49.0) 38.9–59.2
Smoking status at screening
Active smoker 3 3 (100.0) 29.2–100.0
Past smoker 59 23 (39.0) 26.5–52.6
Never-smoker 127 71 (55.9) 46.8–64.7
Time receiving prior crizotinib
Median 105 48 (45.7) 36.0–55.7
Median 84 49 (58.3) 47.1–69.0
Best response to crizotinib
Complete response 1 1 (100) 2.5–100.0
Partial response 84 50 (59.5) 48.3–70.1
Stable disease 43 19 (44.2) 29.1–60.1
Progressive disease 47 21 (44.7) 30.2–59.9
Unknown, N/A, or NE 14 6 (42.9) 17.7–71.1
IRE, independent review committee; RE, response evaluable; CI, conﬁdence interval; ECOG, Eastern Cooperative Oncology Group; PS, performance status;
CNS, central nervous system; N/A, not applicable; NE, not evaluable.
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AEs leading to dose modiﬁcation or interruptions
occurred in 33% of patients (n ¼ 75), whereas AEs
leading to treatment withdrawal were reported in 6% of
patients (n ¼ 14) (Table 4).
Discussion
Alectinib has demonstrated clinical systemic and CNS
efﬁcacy in two pivotal phase II trials, achieving high
response rates and durable responses.17,18 In the pre-
sent analysis, efﬁcacy and safety data were pooled from
these phase II trials, with 15 and 18 months more
follow-up for NP28761 and NP28673, respectively.
These data conﬁrmed the clinical activity and acceptable
safety proﬁle of alectinib in patients with ALK-positive
NSCLC after treatment with crizotinib.
Despite the differences in standard of care for ALK-
positive NSCLC between the United States and the rest of
the world, the patient populations in NP28761 and
NP28673 were very similar, with 80% and 74% of
patients progressing during prior chemotherapy
and crizotinib therapy, respectively. Other baseline
characteristics were also very similar across the two
studies, including patient age (median 54 versus 52
years), proportion of male patients (45% versus 44%),
patients with an ECOG PS of 0 or 1 (90% versus 91%),
and patients with baseline CNS disease (60% versus
61%) in the North American and global studies,
respectively, supporting the rationale for combining
these data sets.
The ORR of 51.3% that we observed in the present
analysis is consistent with the ORRs reported in the in-
dividual primary and updated analyses of NP28673
(49.2% and 50.8%, respectively) and NP28761 (47.8%
and 52.2%, respectively).17,18 In this pooled analysis,
alectinib demonstrated efﬁcacy regardless of prior
treatment with chemotherapy, with an ORR of 49.3% for
patients who received prior chemotherapy compared
with 58.5% for patients who were chemotherapy-naive.
Overall, the safety proﬁle of alectinib in this pooled
analysis was consistent with the data reported in the
primary publications.17,18 Alectinib was well tolerated
and most of the AEs were grade 1/2 in severity, with
only 1% of deaths reported as being treatment related.
During the pooling of these study data, exposure-
response analysis was also performed. Multivariate lo-
gistic regression and Cox proportional hazards analyses
of the efﬁcacy data demonstrated no statistically signif-
icant relationship between alectinib exposure and best
overall response or PFS across the two studies, and lo-
gistic regression analysis demonstrated no statistically
signiﬁcant relationship between alectinib exposure and
safety end points.22 These exploratory analyses conﬁrm
that the alectinib dosing regimen of 600 mg twice daily
provides exposures within the expected plateau range of
response, supporting its selection as the global dosing
regimen.
Crizotinib was the ﬁrst ALK inhibitor to be approved
for the treatment of ALK-positive NSCLC and it is the
current standard of care. Crizotinib prolongs PFS, in-
creases ORR, and provides a greater improvement in
global quality of life compared with chemotherapy in
both previously treated and treatment-naive, ALK-
positive NSCLC.2,3 Ceritinib was also approved for the
treatment of crizotinib-pretreated patients with ALK-
positive NSCLC after achieving ORR rates of 39% to 56%
and a median PFS of 5.7 to 6.9 months in phase I and II
studies.11,12 Recently, ceritinib was also approved in the
ﬁrst-line setting for patients with ALK-positive NSCLC on
the basis of PFS and ORRs superior to those with
chemotherapy reported in the ASCEND-4 trial.14 The
ORR and PFS for ceritinib are comparable with those of
alectinib in this pooled analysis, but in the ASCEND-2
trial,12 ceritinib was associated with high rates of dose
interruptions (76%) and modiﬁcations or discontinua-
tions (54%). In contrast, alectinib demonstrated an
Figure 1. Independent review committee–assessed
progression-free survival of the pooled population (intent-to-
treat population [N ¼ 225]).
Figure 2. Overall survival of the pooled population (intent-
to-treat population [N ¼ 225]).
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acceptable safety proﬁle and good tolerability in this
pooled analysis, as reﬂected by the rate of dose in-
terruptions and modiﬁcations (33%) and the low with-
drawal rate (6%). A recent study of the ALK inhibitor
brigatinib in the same setting as the two alectinib studies
presented here showed an ORR of 45% to 54% and
median PFS of 9.2 to 12.9 months with doses of 90 mg
once daily or 90 mg once daily for 7 days followed by
180 mg once daily, respectively. Compared with alecti-
nib, brigatinib showed comparable rates of dose re-
ductions (7%) and dose interruptions (18%) due to AEs
at the lower dose; however, at the higher dose brigatinib
showed greater rates of dose reductions (20%), dose
interruptions (36%), and discontinuations (8%).23










Patients with 1 AE 84 (97) 135 (98) 1 219 (97)
Constipation 32 (37) 53 (38) 1 85 (38)
Fatigue 33 (38) 43 (31) 7 76 (34)
Peripheral edema 22 (25) 41 (30) 5 63 (28)
Myalgia 22 (25) 35 (25) 0 57 (25)
Nausea 21 (24) 30 (22) 2 51 (23)
Cough 18 (21) 30 (22) 1 48 (21)
Headache 21 (24) 26 (19) 5 47 (21)
Diarrhea 20 (23) 22 (16) 7 42 (19)
Dyspnea 17 (20) 23 (17) 3 40 (18)
Increased aspartate transaminase level 18 (21) 18 (13) 8 36 (16)
Anemia 17 (20) 16 (12) 8 33 (15)
Weight increased 16 (18) 17 (12) 6 33 (15)
Asthenia 2 (2) 30 (22) 20 32 (14)
Upper respiratory tract infection 13 (15) 19 (14) 1 32 (14)
Vomiting 11 (13) 21 (15) 2 32 (14)
Increased alanine transaminase level 16 (18) 15 (11) 7 31 (14)
Rash 8 (9) 22 (16) 7 30 (13)
Back pain 10 (11) 18 (13) 2 28 (12)
Increased blood bilirubin level 9 (10) 18 (13) 3 27 (12)
Increased blood creatine phosphokinase level 20 (23) 6 (4) 19 26 (12)
Dizziness 11 (13) 15 (11) 2 26 (12)
Photosensitivity reaction 10 (11) 16 (12) 1 26 (12)
Arthralgia 10 (11) 15 (11) 0 25 (11)
Insomnia 11 (13) 12 (9) 4 23 (10)
Decreased appetite 5 (6) 17 (12) 6 22 (10)
Upper abdominal pain 4 (5) 17 (12) 7 21 (9)
Nasopharyngitis 3 (3) 16 (12) 9 19 (8)
Increased blood alkaline phosphatase level 12 (14) 5 (4) 10 17 (8)
Hypokalemia 9 (10) 7 (5) 5 16 (7)
Oropharyngeal pain 2 (2) 14 (10) 8 16 (7)
Hypertriglyceridemia 11 (13) 0 13 11 (5)
AE, adverse event; ITT, intent-to-treat.








AE leading to withdrawal from study 2 (2) 12 (9) 14 (6)
AE leading to withdrawal from treatment 2 (2) 12 (9) 14 (6)
AE leading to dose modiﬁcation or interruption 37 (43) 38 (28) 75 (33)
Serious AE leading to withdrawal from treatment 1 (1) 8 (6) 9 (4)
Serious AE leading to dose modiﬁcation or interruption 9 (10) 13 (9) 22 (10)
Related AE leading to withdrawal from treatment 2 (2) 8 (6) 10 (4)
Related AE leading to dose modiﬁcation or interruption 24 (28) 23 (17) 47 (21)
AE, adverse event; ITT, intent-to-treat.
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Here we have reported the systemic efﬁcacy and
safety of the pooled population; in addition, an analysis
of the activity of alectinib on CNS metastases in this
pooled data set has recently been published.24 Alectinib
achieved a CNS ORR of 64.0% (95% CI: 49.2–77.1) with
a CNS DCR of 90.0% (95% CI: 78.2–96.7) and CNS DOR
of 10.8 months (95% CI: 78.2–90.8), showing good CNS
efﬁcacy.
Two ongoing phase III studies are directly comparing
the efﬁcacy of alectinib with crizotinib in patients with
ALK inhibitor–naive ALK-positive NSCLC (ALEX
[NCT02075840] and J-ALEX [JapicCTI-132316]).
Following an interim analysis, results from the J-ALEX
study were released early, as the primary end point of
PFS demonstrated superiority compared with the PFS
with crizotinib treatment (HR ¼ 0.34 [99.6826% CI:
0.17–0.70, stratiﬁed log-rank p < 0.0001]; median PFS
not reached [95% CI: 20.3–NE] versus 10.2 months
[95% CI: 8.2–12.0] for alectinib versus crizotinib).24,25
Grade 3 or 4 AEs were observed at a greater frequency
in the crizotinib arm (52%) than in the alectinib arm
(27%), and rates of drug interruptions were lower with
alectinib than with crizotinib (29% versus 74%,
respectively). Primary data from the global ALEX study
also showed that alectinib had a PFS superior to that
with crizotinib (12-month event-free survival rate,
68.4% [95% CI: 61.0–75.9] with alectinib versus 48.7%
[95% CI: 40.4–56.9] with crizotinib).21
In conclusion, the results from this pooled analysis
showed that alectinib, 600 mg twice daily, demonstrated
clinical activity and was well tolerated in patients with
ALK-positive NSCLC who had progressed while taking
crizotinib. Efﬁcacy was shown in patients who had
received prior chemotherapy, as well as in those who
were chemotherapy naive.
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